Amplification-free Long-read Sequencing Reveals Unforeseen CRISPR-Cas9 Off-target Activity
Overview
Authors
Affiliations
Background: One ongoing concern about CRISPR-Cas9 genome editing is that unspecific guide RNA (gRNA) binding may induce off-target mutations. However, accurate prediction of CRISPR-Cas9 off-target activity is challenging. Here, we present SMRT-OTS and Nano-OTS, two novel, amplification-free, long-read sequencing protocols for detection of gRNA-driven digestion of genomic DNA by Cas9 in vitro.
Results: The methods are assessed using the human cell line HEK293, re-sequenced at 18x coverage using highly accurate HiFi SMRT reads. SMRT-OTS and Nano-OTS are first applied to three different gRNAs targeting HEK293 genomic DNA, resulting in a set of 55 high-confidence gRNA cleavage sites identified by both methods. Twenty-five of these sites are not reported by off-target prediction software, either because they contain four or more single nucleotide mismatches or insertion/deletion mismatches, as compared with the human reference. Additional experiments reveal that 85% of Cas9 cleavage sites are also found by other in vitro-based methods and that on- and off-target sites are detectable in gene bodies where short-reads fail to uniquely align. Even though SMRT-OTS and Nano-OTS identify several sites with previously validated off-target editing activity in cells, our own CRISPR-Cas9 editing experiments in human fibroblasts do not give rise to detectable off-target mutations at the in vitro-predicted sites. However, indel and structural variation events are enriched at the on-target sites.
Conclusions: Amplification-free long-read sequencing reveals Cas9 cleavage sites in vitro that would have been difficult to predict using computational tools, including in dark genomic regions inaccessible by short-read sequencing.
Sari O, Liu Z, Pan Y, Shao X Bioinform Adv. 2025; 5(1):vbae184.
PMID: 39758829 PMC: 11696696. DOI: 10.1093/bioadv/vbae184.
Applications of CRISPR Technologies in Forestry and Molecular Wood Biotechnology.
Cao H, Michels D, Vu G, Gailing O Int J Mol Sci. 2024; 25(21).
PMID: 39519342 PMC: 11547103. DOI: 10.3390/ijms252111792.
Park J, Kim Y, Hwang G, Kang C, Bae S, Cha H Nat Commun. 2024; 15(1):4002.
PMID: 38734692 PMC: 11088699. DOI: 10.1038/s41467-024-48111-9.
Zhao J, Sun X, Tian S, Zhao Z, Yin M, Zhao M BMC Genomics. 2024; 25(1):189.
PMID: 38368357 PMC: 10874558. DOI: 10.1186/s12864-024-10050-6.
Shum C, Han S, Thiruvahindrapuram B, Wang Z, de Rijke J, Zhang B Comput Struct Biotechnol J. 2024; 23:638-647.
PMID: 38283851 PMC: 10819409. DOI: 10.1016/j.csbj.2023.12.036.